Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice

References

• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. DOI:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Tebboth A, Gayle A, et al. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice. NPJ Prim Care Respir Med. 2017; 27(43). DOI:10.1038/s41533-017-0040-z
   Google Scholar
• Koblizek V, Milenkovic B, Barczyk A, et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE study. Eur Respir J. 2017;49(5):1601446. DOI:10.1183/13993003.01446-2016
   PubMed Web of Science ®Google Scholar
• Ghosh S, Anderson WH, Putcha N, Current and former investigators of the SPIROMICS sites and reading centers, et al. Alignment of inhaled chronic obstructive pulmonary disease therapies with published strategies. Analysis of the global initiative for chronic obstructive lung disease recommendations in SPIROMICS. Ann Am Thorac Soc. 2019;16(2):200–208. DOI:10.1513/AnnalsATS.201804-283OC
   PubMed Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–537. DOI:10.1183/09031936.00128914
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease (2019 Report). http://goldcopd.org/gold-2019-global-strategy-diagnosis-management-prevention-copd/. 2019.
   Google Scholar
• Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020;55(6):2000351. DOI:10.1183/13993003.00351-2020
   PubMed Web of Science ®Google Scholar
• Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60(6):480–487. DOI:10.1136/thx.2004.034280
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–1294. DOI:10.1056/NEJMoa1407154
   PubMed Web of Science ®Google Scholar
• Rossi A, van der Molen T, del OR, et al. Instead: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD. Eur Respir J. 2014;44(6):1548–1556. DOI:10.1183/09031936.00126814
   PubMed Web of Science ®Google Scholar
• Chapman KR, Hurst JR, Frent S-M, et al. Long-Term triple therapy De-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–339. DOI:10.1164/­rccm.201803-0405OC
   PubMed Web of Science ®Google Scholar
• Calverley P. Knowing when to stop: inhaled corticosteroids and COPD. Eur Respir J. 2015;46(5):1236–1238. DOI:10.1183/13993003.01372-2015
   PubMed Web of Science ®Google Scholar
• Suissa S, Rossi A. Weaning from inhaled corticosteroids in COPD: the evidence. Eur Respir J. 2015;46(5):1232–1235. DOI:10.1183/13993003.00282-2015
   PubMed Web of Science ®Google Scholar
• Tashkin DP. To withdraw or not to withdraw inhaled corticosteroids from triple therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(3):292–294. DOI:10.1164/rccm.201805-0979ED
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Shaikh A, Tetzlaff K, et al. Effect of inhaled corticosteroid withdrawal on chronic obstructive pulmonary disease exacerbations in patients taking triple therapy at baseline. Int J Chron Obstruct Pulmon Dis. 2020; 15:2879–2888. DOI:10.2147/COPD.S237408
   PubMed Web of Science ®Google Scholar
• Han MK, Criner GJ, Dransfield MT, et al. The effect of ICS withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. Am J Respir Crit Care Med. 2020;202(9):1237–1243. DOI:10.1164/rccm.201912-2478OC
   PubMed Web of Science ®Google Scholar
• Magnussen H, Lucas S, Lapperre T, Respiratory Effectiveness Group (REG), et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study. Respir Res. 2021;22(1):25. DOI:10.1186/s12931-021-01615-0
   PubMed Web of Science ®Google Scholar
• Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: Clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44(3):827–836. DOI:10.1093/ije/dyv098
   PubMed Web of Science ®Google Scholar
• Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4–14. DOI:10.1111/j.1365-2125.2009.03537.x
   PubMed Web of Science ®Google Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740–1740. DOI:10.1093/ije/dyz034
   PubMed Web of Science ®Google Scholar
• Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(5):686–689. DOI:10.1592/phco.23.5.686.32205
   PubMed Web of Science ®Google Scholar
• Quint JK, Mullerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. DOI:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. Eur Respir J. 2017;49(5):1602245. DOI:10.1183/13993003.02245-2016
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Long-Acting bronchodilator initiation in COPD and the risk of adverse cardiopulmonary events: a population-based comparative safety study. Chest. 2017;151(1):60–67. DOI:10.1016/j.chest.2016.08.001
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med. 2018;6(11):855–862. DOI:10.1016/S2213-2600(18)30368-0
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice . Chest. 2019;155(6):1158–1165. DOI:10.1016/j.chest.2019.03.005
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest. 2020;157(4):846–855.
   Google Scholar
• Suissa S, Moodie EE, Dell’Aniello S. Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores. Pharmacoepidemiol Drug Saf. 2017;26(4):459–468. DOI:10.1002/pds.4107
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016; 8:771–782. DOI:10.2147/CLEP.S117867
   PubMed Web of Science ®Google Scholar
• Meropol SB, Metlay JP. Accuracy of pneumonia hospital admissions in a primary care electronic medical record database. Pharmacoepidemiol Drug Saf. 2012;21(6):659–665. DOI:10.1002/pds.3207
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: cohort study in real-world clinical practice. Chest. 2020;157(4):846–855. DOI:10.1016/j.chest.2019.11.007
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell’Aniello S, Ernst P. Comparative effectiveness of initial LAMA versus LABA in COPD: real-world cohort study. Copd. 2021;18(1):1–8. DOI:10.1080/15412555.2021.1877649
   PubMedGoogle Scholar
• Suissa S. Immeasurable time bias in observational studies of drug effects on mortality. Am J Epidemiol. 2008;168(3):329–335. DOI:10.1093/aje/kwn135
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. DOI:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Jamieson DB, Matsui EC, Belli A, et al. Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188(2):187–192. DOI:10.1164/rccm.201211-2103OC
   PubMed Web of Science ®Google Scholar
• Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007. DOI:10.1378/chest.14-0655
   PubMed Web of Science ®Google Scholar
• Suissa S. Inhaled corticosteroid withdrawal in chronic obstructive pulmonary disease: can impact help? Am J Respir Crit Care Med. 2020;202(9):1202–1204. DOI:10.1164/rccm.202006-2600ED
   PubMed Web of Science ®Google Scholar
• Pavord ID. Counterpoint: should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30%<FEV1 < 50% predicted) COPD? No. Chest 2018;153: 782–784.
   Google Scholar
• Chalmers JD. Point: should an attempt be made to withdraw inhaled corticosteroids in all patients with stable GOLD 3 (30%<FEV1 < 50% predicted) COPD? Yes. Chest 2018;153:778–782.
   Google Scholar
• Suissa S, Ernst P. Precision medicine urgency: the case of inhaled corticosteroids in COPD. Chest. 2017;152(2):227–231. DOI:10.1016/j.chest.2017.05.020
   PubMed Web of Science ®Google Scholar
• Sidhaye VK, Nishida K, Martinez FJ. Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev. 2018;27(149):180022. DOI:10.1183/16000617.0022-2018
   PubMed Web of Science ®Google Scholar
• Hillas G, Papaporfyriou A, Dimakou K, et al. Pharmacological treatment of stable COPD: need for a simplified approach. Postgrad Med. 2020;132(2):126–131. DOI:10.1080/00325481.2019.1706996
   PubMed Web of Science ®Google Scholar
• Hillas G, Papaporfyriou A, Dimakou K, et al. Updated simplified approach of pharmacological treatment of stable COPD: do common co-morbidities have a role? Postgrad Med. 2021;133(8):873–874. DOI:10.1080/00325481.2021.1962612
   PubMed Web of Science ®Google Scholar
• Rebordosa C, Plana E, Aguado J, et al. GOLD assessment of COPD severity in the clinical practice research datalink (CPRD). Pharmacoepidemiol Drug Saf. 2019;28(2):126–133. DOI:10.1002/pds.4448
   PubMed Web of Science ®Google Scholar